Table 2.

Participant Clinical Characteristics (n = 55)

	N	%
Diagnosis
Schizoaffective disorder	19	34.5
Schizophrenia	36	65.5
Medication class*
No atypical antipsychotics	3	5.5
Typical antipsychotics	6	10.9
Atypical antipsychotics	34	61.8
Both typical/atypical antipsychotics	2	3.6
	M±SD	Range
MCCB global	36.99 ± 8.93	19–65
CAINS motivation and pleasure	25.56 ± 3.94	18–34
CAINS expression	1.89 ± 2.60	0–13
SANS diminished motivation	22.04 ± 3.87	13–29
SANS diminished expression	4.43 ± 5.47	0–20
BPRS positive subscale	5.31 ± 2.05	3–10
CDSS depression	1.73 ± 1.74	0–7
BIS insight	8.91 ± 2.19	4–12
ABS asocial beliefs	6.62 ± 3.49	1–15
QLS-3 intrinsic motivation	6.75 ± 2.51	1–13
DPAS defeatist attitudes	52.75 ± 15.73	23–87
UPSA	63.43 ± 17.59	19–90
SSPA	3.02 ± 0.52	2.01–3.96
SLOF	3.82 ± 0.76	1.63–5
ILSS	0.81 ± 0.06	0.65–0.91

Note:

^*n = 45.

ABS = Asocial Belief Scale; BIS=Birchwood Insight Scale; BPRS=Brief Psychiatric Rating Scale; CAINS=Clinical Assessment Interview for Negative Symptoms; CDSS=Calgary Depression Scale for Schizophrenia; DPAS = Defeatist Performance Attitude Scale; ILSS=Independent Living Skills Survey; MCCB = MATRICS Consensus Cognitive Battery; QLS-3 = Quality of Life Scale; SANS=Scale for the Assessment of Negative Symptoms; SLOF=Specific Level of Functioning; SSPA=Social Skills Performance Assessment; UPSA-B=UCSD Performance-based Skills Assessment; WRAT-IV=Wide Range Achievement Test-Fourth Edition. Atypical antipsychotics: Aripiprazole, Clozapine, Iloperidone, Lurasidone, Olanzapine, Quetiapine, Risperidone, Ziprasidone; Typical antipsychotics: Fluphenazine, Haloperidol, Perphenazine.